Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,172 GBX | -0.60% | -0.75% | +14.83% |
May. 15 | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- With a 2024 P/E ratio at 22.16 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.83% | 239B | B+ | ||
+31.37% | 588B | B | ||
-2.60% | 364B | C+ | ||
+20.83% | 326B | B- | ||
+5.69% | 285B | C+ | ||
+9.93% | 210B | B- | ||
-6.95% | 200B | A+ | ||
+10.77% | 167B | C+ | ||
+0.10% | 161B | C+ | ||
+0.89% | 124B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC